Page 2 - Sanofi India

Sanofi India: Strong balance sheet, high cash reserves positives for stock

Products in the price control list and growth of the non-power brand portfolio will be key monitorables

Sanofi India names Rodolfo Hrosz managing director effective June 1

He will transition from being Sanofi's GM, Consumer Healthcare business in Brazil to the new role in India as soon as regulatory approvals are in place

Sensex tanks 2,702pts, ends below 55K; Nifty gives up 16,250; Brent at $105

Closing Bell: Benchmark indices clocked their biggest one-day fall since March 2020 as Russia invaded Ukraine, rattling global markets

Stocks to Watch: Indian Hotels, TCS, Dabur, Bosch, Ashok Leyland, Insurance

Insurance related stocks could see some action as the India Protection Quotient (IPQ) survey 4, stated that term insurance ownership has gone up from 36 per cent to 43 per cent in the last two years.

Sanofi India Managing Director Rajaram Narayanan resigns

Drug firm Sanofi India on Thursday said its Managing Director Rajaram Narayanan has put in his papers

Sanofi India net profit at Rs 530 crore in September quarter

The company's revenue from operations rose to Rs 754.5 crore as compared to Rs 686.6 crore in the year-ago period

Sanofi India reports second quarter net profit at Rs 178.3 crore

Revenue from operations of the company stood at Rs 789.1 crore for the quarter under consideration

Weak Q3 show, margin pressures to keep Sanofi stock under pressure

Growth led by power brands and new launches could recover as pandemic impact wanes

Stocks to watch: Tata Consumer, GAIL, NTPC, SBI Card, Sanofi India, REC

SBI Cards and Payment Services had raised Rs 550 crore by issuing bonds on a private placement basis

Sanofi India board approves special dividend of Rs 240 per share

The company reported net profit of Rs 123 cr for the quarter ended December, 31 2020, an increase of 27% from year-ago period

Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says

In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data

Sanofi posts stronger-than-expected result in Q4, eyes more cost cuts

The French company, which stunned investors last year with the delay of a COVID-19 vaccine candidate, confirmed an operating income margin target of 30%

Sanofi India: Long-term investors advised to consider the stock on dips

Analysts see 19 per cent annual growth in earnings during FY20-22 with significant rise in return ratios post sale of a facility

Sanofi and GSK launch trial for protein-based coronavirus vaccine

PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments

Sanofi more confident about its coronavirus vaccines, trials next month

The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the Covid-19 pandemic

Sanofi India gains 5%, hits 52-week high; stock soars 8% so far in August

Early this week, the comany's parent firm Sanofi said it will acquire all of the outstanding shares of US-based Principia Biopharma Inc. for a total approximate aggregate equity value of $3.68 billion

Next target for Nifty is seen at 11,550: Vinay Rajani of HDFC Securities

Traders are advised to hold Nifty longs with 11,200 stoploss and keep it trailing as Nifty rises

French group Sanofi to buy US firm Principia Biopharma for $3.7 billion

PARIS (Reuters) - French healthcare company Sanofi SA has agreed to buy U.S. company Principia Biopharma Inc for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and development (R&D) areas.

Nifty outlook and stock pick by HDFC Sec: Buy UltraTech Cement, Sanofi

NIfty has been forming higher tops and higher bottoms on the daily charts. Nifty is placed above 20,50,100 and 200 days moving averages, indicating bullish trend on all time frames

Sanofi India: Sturdy balance sheet, cash-generation augur well for company

High growth visibility in chronics, strong balance sheet will help sustain premium valuation